Suven Life Sciences Limited (SUVEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Suven Life Sciences Limited (SUVEN) has a cash flow conversion efficiency ratio of -0.368x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-1.03 Billion ≈ $-11.18 Million USD) by net assets (Rs2.81 Billion ≈ $30.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SUVEN net asset quality score to measure how much of total assets are equity-financed.
Suven Life Sciences Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Suven Life Sciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Suven Life Sciences Limited cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Suven Life Sciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Suven Life Sciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Green Cross Corp
KO:006280
|
0.094x |
|
Sun Country Airlines Holdings Inc
NASDAQ:SNCY
|
0.045x |
|
Tanla Platforms Limited
NSE:TANLA
|
0.074x |
|
RHÖN-KLINIKUM Aktiengesellschaft
XETRA:RHK
|
-0.019x |
|
Flotek Industries Inc
NYSE:FTK
|
0.000x |
|
Cera Sanitaryware Limited
NSE:CERA
|
0.052x |
|
Zhejiang Xinhua Chemical Co Ltd
SHG:603867
|
0.034x |
|
CH. Karnchang Public Company Limited
BK:CK-R
|
0.104x |
Annual Cash Flow Conversion Efficiency for Suven Life Sciences Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Suven Life Sciences Limited from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see SUVEN company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs1.10 Billion ≈ $11.89 Million |
Rs-1.48 Billion ≈ $-16.06 Million |
-1.350x | -215.69% |
| 2024-03-31 | Rs2.70 Billion ≈ $29.20 Million |
Rs-1.15 Billion ≈ $-12.49 Million |
-0.428x | -55.59% |
| 2023-03-31 | Rs3.75 Billion ≈ $40.59 Million |
Rs-1.03 Billion ≈ $-11.16 Million |
-0.275x | +79.28% |
| 2022-03-31 | Rs961.45 Million ≈ $10.40 Million |
Rs-1.28 Billion ≈ $-13.79 Million |
-1.327x | -49.20% |
| 2021-03-31 | Rs1.08 Billion ≈ $11.68 Million |
Rs-960.24 Million ≈ $-10.38 Million |
-0.889x | +34.25% |
| 2020-03-31 | Rs1.43 Billion ≈ $15.50 Million |
Rs-1.94 Billion ≈ $-20.96 Million |
-1.352x | -3261.03% |
| 2019-03-31 | Rs8.31 Billion ≈ $89.87 Million |
Rs355.49 Million ≈ $3.84 Million |
0.043x | -53.06% |
| 2018-03-31 | Rs7.67 Billion ≈ $82.99 Million |
Rs699.36 Million ≈ $7.56 Million |
0.091x | -44.15% |
| 2017-03-31 | Rs6.67 Billion ≈ $72.13 Million |
Rs1.09 Billion ≈ $11.77 Million |
0.163x | +39.04% |
| 2016-03-31 | Rs5.95 Billion ≈ $64.40 Million |
Rs698.78 Million ≈ $7.56 Million |
0.117x | -54.10% |
| 2015-03-31 | Rs5.59 Billion ≈ $60.49 Million |
Rs1.43 Billion ≈ $15.46 Million |
0.256x | -44.27% |
| 2014-03-31 | Rs2.64 Billion ≈ $28.60 Million |
Rs1.21 Billion ≈ $13.12 Million |
0.459x | +130.90% |
| 2013-03-31 | Rs1.54 Billion ≈ $16.70 Million |
Rs306.86 Million ≈ $3.32 Million |
0.199x | -24.39% |
| 2012-03-31 | Rs1.28 Billion ≈ $13.79 Million |
Rs335.07 Million ≈ $3.62 Million |
0.263x | +503.70% |
| 2011-03-31 | Rs1.27 Billion ≈ $13.71 Million |
Rs55.16 Million ≈ $596.55K |
0.044x | -60.24% |
| 2010-03-31 | Rs1.18 Billion ≈ $12.77 Million |
Rs129.25 Million ≈ $1.40 Million |
0.109x | -63.45% |
| 2009-03-31 | Rs1.14 Billion ≈ $12.38 Million |
Rs342.73 Million ≈ $3.71 Million |
0.299x | +709.03% |
| 2008-03-31 | Rs1.06 Billion ≈ $11.51 Million |
Rs39.38 Million ≈ $425.92K |
0.037x | -76.86% |
| 2007-03-31 | Rs1.02 Billion ≈ $10.98 Million |
Rs162.41 Million ≈ $1.76 Million |
0.160x | +161.76% |
| 2006-03-31 | Rs902.12 Million ≈ $9.76 Million |
Rs55.13 Million ≈ $596.25K |
0.061x | +135.07% |
| 2005-03-31 | Rs811.85 Million ≈ $8.78 Million |
Rs21.11 Million ≈ $228.26K |
0.026x | -- |
About Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candida… Read more